The Use of Cerebellar Hypoperfusion Assessment in the Differential Diagnosis of Multiple System Atrophy with Parkinsonism and Progressive Supranuclear Palsy-Parkinsonism Predominant
Abstract
:1. Introduction
2. Method
2.1. SPECT
2.2. Statistical Analysis
3. Results
4. Discussion
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Louis, E.K.S.; Boeve, B.F. REM Sleep Behavior Disorder: Diagnosis, Clinical Implications, and Future Directions. Mayo Clin. Proc. 2017, 92, 1723–1736. [Google Scholar] [CrossRef] [PubMed]
- Kauppila, L.A.; Holter, S.E.T.; van de Warrenburg, B.; Bloem, B.R. A Guide for the Differential Diagnosis of Multiple System Atrophy in Clinical Practice. J. Park. Dis. 2022, 12, 2015–2027. [Google Scholar] [CrossRef] [PubMed]
- Wenning, G.K.; Stankovic, I.; Vignatelli, L.; Fanciulli, A.; Calandra-Buonaura, G.; Seppi, K.; Palma, J.; Meissner, W.G.; Krismer, F.; Berg, D.; et al. The Movement Disorder Society Criteria for the Diagnosis of Multiple System Atrophy. Mov. Disord. 2022, 37, 1131–1148. [Google Scholar] [CrossRef] [PubMed]
- Yamawaki, T. Diagnosis of MSA-P and PSP-P in Early Stage. Brain Nerve. 2020, 72, 331–343. [Google Scholar] [CrossRef]
- Höglinger, G.U.; Respondek, G.; Stamelou, M.; Kurz, C.; Josephs, K.A.; Lang, A.E.; Mollenhauer, B.; Müller, U.; Nilsson, C.; Whitwell, J.L.; et al. Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria. Mov. Disord. 2017, 32, 853–864. [Google Scholar] [CrossRef] [PubMed]
- Krzosek, P.; Madetko, N.; Migda, A.; Migda, B.; Jaguś, D.; Alster, P. Differential Diagnosis of Rare Subtypes of Progressive Supranuclear Palsy and PSP-Like Syndromes—Infrequent Manifestations of the Most Common Form of Atypical Parkinsonism. Front. Aging Neurosci. 2022, 14, 804385. [Google Scholar] [CrossRef]
- Necpál, J.; Borsek, M.; Jeleňová, B. “Parkinson’s disease” on the way to progressive supranuclear palsy: A review on PSP-parkinsonism. Neurol. Sci. 2021, 42, 4927–4936. [Google Scholar] [CrossRef]
- Colosimo, C.; PRIAMO STUDY GROUP; Morgante, L.; Antonini, A.; Barone, P.; Avarello, T.P.; Bottacchi, E.; Cannas, A.; Ceravolo, M.G.; Ceravolo, R.; et al. Non-motor symptoms in atypical and secondary parkinsonism: The PRIAMO study. J. Neurol. 2009, 257, 5–14. [Google Scholar] [CrossRef]
- Gerstenecker, A.; Duff, K.; Mast, B.; Litvan, I. Behavioral abnormalities in progressive supranuclear palsy. Psychiatry Res. 2013, 210, 1205–1210. [Google Scholar] [CrossRef] [Green Version]
- Alster, P.; Madetko, N.; Koziorowski, D.; Friedman, A. Microglial Activation and Inflammation as a Factor in the Pathogenesis of Progressive Supranuclear Palsy (PSP). Front. Neurosci. 2020, 14, 893. [Google Scholar] [CrossRef]
- Compagnoni, G.M.; Di Fonzo, A. Understanding the pathogenesis of multiple system atrophy: State of the art and future perspectives. Acta Neuropathol. Commun. 2019, 7, 113. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Gilman, S.; Wenning, G.; Low, P.A.; Brooks, D.; Mathias, C.J.; Trojanowski, J.Q.; Wood, N.; Colosimo, C.; Durr, A.; Fowler, C.J.; et al. Second consensus statement on the diagnosis of multiple system atrophy. Neurology 2008, 71, 670–676. [Google Scholar] [CrossRef] [PubMed]
- Aghakhanyan, G.; Rullmann, M.; Rumpf, J.; Schroeter, M.L.; Scherlach, C.; Patt, M.; Brendel, M.; Koglin, N.; Stephens, A.W.; Classen, J.; et al. Interplay of tau and functional network connectivity in progressive supranuclear palsy: A [18F]PI-2620 PET/MRI study. Eur. J. Pediatr. 2022, 50, 103–144. [Google Scholar] [CrossRef] [PubMed]
- Song, M.; Beyer, L.; Kaiser, L.; Barthel, H.; van Eimeren, T.; Marek, K.; Nitschmann, A.; Scheifele, M.; Palleis, C.; Respondek, G.; et al. Binding characteristics of [18F]PI-2620 distinguish the clinically predicted tau isoform in different tauopathies by PET. J. Cereb. Blood Flow Metab. 2021, 41, 2957–2972. [Google Scholar] [CrossRef]
- Song, M.; Scheifele, M.; Barthel, H.; van Eimeren, T.; Beyer, L.; Marek, K.; Eckenweber, F.; Palleis, C.; Kaiser, L.; Finze, A.; et al. Feasibility of short imaging protocols for [18F]PI-2620 tau-PET in progressive supranuclear palsy. Eur. J. Nucl. Med. 2021, 48, 3872–3885. [Google Scholar] [CrossRef]
- Alster, P.; Madetko, N.K.; Koziorowski, D.M.; Królicki, L.; Budrewicz, S.; Friedman, A. Accumulation of Tau Protein, Me-tabolism and Perfusion-Application and Efficacy of Positron Emission Tomography (PET) and Single Photon Emission Computed Tomography (SPECT) Imaging in the Examination of Progressive Supranuclear Palsy (PSP) and Corticobasal Syndrome (CBS). Front. Neurol. 2019, 14, 101. [Google Scholar]
- Tomše, P.; Rebec, E.; Studen, A.; Perovnik, M.; Rus, T.; Ležaić, L.; Tang, C.C.; Eidelberg, D.; Trošt, M. Abnormal metabolic covariance patterns associated with multiple system atrophy and progressive supranuclear palsy. Phys. Medica 2022, 98, 131–138. [Google Scholar] [CrossRef]
- Akdemir, Ü.Ö.; Tokçaer, A.B.; Karakuş, A.; Kapucu, L. Brain 18F-FDG PET Imaging in the Differential Diagnosis of Parkinsonism. Clin. Nucl. Med. 2014, 39, e220–e226. [Google Scholar] [CrossRef]
- Juh, R.; Kim, J.; Moon, D.; Choe, B.; Suh, T. Different metabolic patterns analysis of Parkinsonism on the 18F-FDG PET. Eur. J. Radiol. 2004, 51, 223–233. [Google Scholar] [CrossRef]
- Amtage, F.; Maurer, C.; Hellwig, S.; Tüscher, O.; Kreft, A.; Weiller, C.; Rijntjes, M.; Winkler, C.; Meyer, P.T. Functional correlates of vertical gaze palsy and other ocular motor deficits in PSP: An FDG-PET study. Park. Relat. Disord. 2014, 20, 898–906. [Google Scholar] [CrossRef]
- Alster, P.; Nieciecki, M.; Migda, B.; Kutyłowski, M.; Madetko, N.; Duszyńska-Wąs, K.; Charzyńska, I.; Koziorowski, D.; Królicki, L.; Friedman, A. The Strengths and Obstacles in the Differential Diagnosis of Progressive Supranuclear Palsy—Parkinsonism Predominant (PSP-P) and Multiple System Atrophy (MSA) Using Magnetic Resonance Imaging (MRI) and Perfusion Single Photon Emission Computed Tomography (SPECT). Diagnostics 2022, 12, 385. [Google Scholar] [CrossRef] [PubMed]
- Alster, P.; Madetko-Alster, N.; Migda, B.; Nieciecki, M.; Koziorowski, D.; Królicki, L. The Assessment of Subregions in the Frontal Lobe May Be Feasible in the Differential Diagnosis of Progressive Supranuclear Palsy—Parkinsonism Predominant (PSP-P) and Multiple System Atrophy (MSA). Diagnostics 2022, 12, 2421. [Google Scholar] [CrossRef] [PubMed]
- Tzourio-Mazoyer, N.; Landeau, B.; Papathanassiou, D.; Crivello, F.; Etard, O.; Delcroix, N.; Mazoyer, B.; Joliot, M. Auto-mated Anatomical Labeling of Activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single- subject brain. NeuroImage 2002, 15, 273–289. [Google Scholar] [CrossRef] [PubMed]
- Collins, D.L.; Zijdenbos, A.P.; Kollokian, V.; Sled, J.G.; Kabani, N.J.; Holmes, C.J.; Evans, A.C. Design and con-struction of a realistic digital brain phantom—IEEE Transactions on Medical. Imaging 1998, 17, 463–468. [Google Scholar] [CrossRef] [PubMed]
- Murakami, N.; Sako, W.; Haji, S.; Furukawa, T.; Otomi, Y.; Otsuka, H.; Izumi, Y.; Harada, M.; Kaji, R. Differences in cerebellar perfusion between Parkinson’s disease and multiple system atrophy. J. Neurol. Sci. 2020, 409, 116627. [Google Scholar] [CrossRef] [PubMed]
- Scotton, W.J.; Bocchetta, M.; Todd, E.; Cash, D.M.; Oxtoby, N.; VandeVrede, L.; Heuer, H.; Alexander, D.C.; Rowe, J.B.; Morris, H.R.; et al. A data-driven model of brain volume changes in progressive supranuclear palsy. Brain Commun. 2022, 4, fcac098. [Google Scholar] [CrossRef] [PubMed]
- Alster, P.; Nieciecki, M.; Koziorowski, D.M.; Cacko, A.; Charzyńska, I.; Królicki, L.; Friedman, A. Thalamic and cerebellar hypoperfusion in single photon emission computed tomography may differentiate multiple system atrophy and progressive supranuclear palsy. Medicine 2019, 98, e16603. [Google Scholar] [CrossRef]
- Madetko, N.; Alster, P.; Kutyłowski, M.; Migda, B.; Nieciecki, M.; Koziorowski, D.; Królicki, L. Is MRPI 2.0 More Useful than MRPI and M/P Ratio in Differential Diagnosis of PSP-P with Other Atypical Parkinsonisms? J. Clin. Med. 2022, 11, 2701. [Google Scholar] [CrossRef]
- Alster, P.; Madetko, N.; Koziorowski, D.; Friedman, A. Progressive Supranuclear Palsy—Parkinsonism Predominant (PSP-P)—A Clinical Challenge at the Boundaries of PSP and Parkinson’s Disease (PD). Front. Neurol. 2020, 11, 180. [Google Scholar] [CrossRef]
- Beliveau, V.; Müller, C.; Steiger, R.; Gizewski, E.R.; Poewe, W.; Seppi, K.; Scherfler, C. Characterization and diagnostic potential of R2* in early-stage progressive supranuclear palsy variants. Park. Relat. Disord. 2022, 101, 43–48. [Google Scholar] [CrossRef]
- Schulz, I.; Kruse, N.; Gera, R.G.; Kremer, T.; Cedarbaum, J.; Barbour, R.; Zago, W.; Schade, S.; Otte, B.; Bartl, M.; et al. Systematic Assessment of 10 Biomarker Candidates Focusing on α-Synuclein-Related Disorders. Mov. Disord. 2021, 36, 2874–2887. [Google Scholar] [CrossRef] [PubMed]
- Compta, Y.; Giraldo, D.M.; Muñoz, E.; Antonelli, F.; Fernández, M.; Bravo, P.; Soto, M.; Cámara, A.; Torres, F.; Martí, M.J.; et al. Cerebrospinal fluid levels of coenzyme Q10 are reduced in multiple system atrophy. Park. Relat. Disord. 2017, 46, 16–23. [Google Scholar] [CrossRef] [PubMed]
- Morris, H.R. Blood based biomarkers for movement disorders. Acta Neurol. Scand. 2022, 146, 353–361. [Google Scholar] [CrossRef] [PubMed]
MSA-P | PSP-P | |
---|---|---|
age (mean) | 62.5 years | 72 years |
disease duration | 4–6 years | 4–6 years |
UPDRS part III ON state (mean) | 35 points | 32 points |
UPDRS part III OFF state (mean) | 38 points | 38.3 points |
Hoehn & Yahr (mean) | 2 | 2.5 |
LEDD (mean) | 850 mg | 1200 mg |
ROI—CEREBELLUM | Total (n = 31) | MSA-P (n = 20) | PSP-P (n = 11) | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Median | Lower Quartile | Upper Quartile | Quartile Range | Median | Lower Quartile | Upper Quartile | Quartile Range | Median | Lower Quartile | Upper Quartile | Quartile Range | |
cerebellum + vermis SD | −1.60 | −3.90 | −0.10 | 3.80 | −2.00 | −4.00 | −1.35 | 2.65 | −0.50 | −1.60 | 0.20 | 1.80 |
ant. quadrangular lobule (H IV-V) L SD | −1.20 | −2.40 | 0.30 | 2.70 | −1.30 | −2.55 | −0.05 | 2.50 | −0.60 | −1.60 | 0.50 | 2.10 |
ant. quadrangular lobule (H IV-V) R SD | −0.20 | −1.70 | 0.50 | 2.20 | −0.50 | −2.00 | 0.70 | 2.70 | 0.00 | −0.70 | 0.50 | 1.20 |
anterior quadrangular lobule 1 L SD | −1.60 | −2.50 | −0.10 | 2.40 | −1.70 | −2.75 | −0.90 | 1.85 | −1.30 | −1.90 | 0.70 | 2.60 |
anterior quadrangular lobule 1 R SD | −0.90 | −2.40 | 0.30 | 2.70 | −1.30 | −2.70 | −0.35 | 2.35 | 0.20 | −1.20 | 0.70 | 1.90 |
anterior quadrangular lobule 2 L SD | −2.10 | −3.60 | −0.50 | 3.10 | −2.45 | −4.35 | −1.80 | 2.55 | −1.00 | −2.10 | 0.00 | 2.10 |
anterior quadrangular lobule 2 R SD | −1.50 | −3.40 | −0.60 | 2.80 | −2.35 | −3.95 | −0.80 | 3.15 | −0.70 | −2.40 | 0.40 | 2.80 |
anterior quadrangular lobule (H IV and V) L SD | −1.90 | −5.40 | −0.10 | 5.30 | −2.40 | −6.45 | −1.45 | 5.00 | 0.00 | −1.30 | 0.80 | 2.10 |
anterior quadrangular lobule (H IV and V) R SD | −0.60 | −3.30 | 0.60 | 3.90 | −1.55 | −3.95 | 0.35 | 4.30 | 0.50 | −0.60 | 1.60 | 2.20 |
simple lobule (H VI-VII) L SD | −0.10 | −1.00 | 1.20 | 2.20 | −0.40 | −1.55 | 0.70 | 2.25 | 0.10 | −0.40 | 1.40 | 1.80 |
simple lobule (H VI-VII) R SD | −0.30 | −1.10 | 1.00 | 2.10 | −0.15 | −0.85 | 1.35 | 2.20 | −0.70 | −1.30 | 0.20 | 1.50 |
cerebellar nuclei L SD | 0.20 | −0.70 | 1.40 | 2.10 | −0.25 | −1.20 | 0.65 | 1.85 | 1.50 | −0.50 | 2.10 | 2.60 |
cerebellar nuclei R SD | 0.50 | −0.70 | 1.70 | 2.40 | 0.80 | −0.80 | 1.45 | 2.25 | 0.30 | −0.70 | 2.30 | 3.00 |
nodule (X) L SD | −2.90 | −4.90 | −1.20 | 3.70 | −2.95 | −5.00 | −1.80 | 3.20 | −2.80 | −4.70 | 0.10 | 4.80 |
nodule (X) R SD | −2.90 | −3.80 | −0.70 | 3.10 | −3.05 | −3.70 | −1.35 | 2.35 | −1.00 | −3.80 | 0.00 | 3.80 |
superior semiluminar lobule; first crus of antiform lobule (H VII a) L SD | −1.00 | −1.70 | 0.20 | 1.90 | −1.35 | −1.85 | 0.20 | 2.05 | −0.40 | −1.50 | 0.20 | 1.70 |
superior semiluminar lobule; first crus of antiform lobule (H VII a) R SD | −0.30 | −1.50 | 0.20 | 1.70 | −0.20 | −2.05 | 0.20 | 2.25 | −0.50 | −1.30 | 0.10 | 1.40 |
simple lobule (HVI) superior semiluminar lobule (first crus of antiform lobule (H VII) L SD | −0.90 | −1.90 | −0.10 | 1.80 | −1.30 | −2.10 | 0.10 | 2.20 | −0.80 | −1.80 | −0.10 | 1.70 |
simple lobule (HVI) superior semiluminar lobule (first crus of antiform lobule (H VII) R SD | −0.70 | −1.60 | 0.80 | 2.40 | −0.30 | −1.35 | 0.85 | 2.20 | −1.10 | −1.80 | 0.00 | 1.80 |
CEREBELLUM—ROI | P |
---|---|
cerebellum + vermis SD | 0.0474 |
ant. quadrangular lobule (H IV-V) L SD | 0.0863 |
ant. quadrangular lobule (H IV-V) R SD | 0.3856 |
anterior quadrangular lobule 1 L SD | 0.1423 |
anterior quadrangular lobule 1 R SD | 0.0572 |
anterior quadrangular lobule 2 L SD | 0.0334 |
anterior quadrangular lobule 2 R SD | 0.0285 |
anterior quadrangular lobule (H IV and V) L SD | 0.0015 |
anterior quadrangular lobule (H IV and V) R SD | 0.014 |
simple lobule (H VI-VII) L SD | 0.3626 |
simple lobule (H VI-VII) R SD | 0.2309 |
cerebellar nuclei L SD | 0.0601 |
cerebellar nuclei R SD | 0.9341 |
nodule (X) L SD | 0.342 |
nodule (X) R SD | 0.1862 |
superior semiluminar lobule; first crus of antiform lobule (H VII a) L SD | 0.397 |
superior semiluminar lobule; first crus of antiform lobule (H VII a) R SD | 0.8685 |
simple lobule (HVI) superior semiluminar lobule (first crus of antiform lobule (H VII) L SD | 0.6645 |
simple lobule (HVI) superior semiluminar lobule (first crus of antiform lobule (H VII) R SD | 0.3112 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Madetko-Alster, N.; Alster, P.; Migda, B.; Nieciecki, M.; Koziorowski, D.; Królicki, L. The Use of Cerebellar Hypoperfusion Assessment in the Differential Diagnosis of Multiple System Atrophy with Parkinsonism and Progressive Supranuclear Palsy-Parkinsonism Predominant. Diagnostics 2022, 12, 3022. https://doi.org/10.3390/diagnostics12123022
Madetko-Alster N, Alster P, Migda B, Nieciecki M, Koziorowski D, Królicki L. The Use of Cerebellar Hypoperfusion Assessment in the Differential Diagnosis of Multiple System Atrophy with Parkinsonism and Progressive Supranuclear Palsy-Parkinsonism Predominant. Diagnostics. 2022; 12(12):3022. https://doi.org/10.3390/diagnostics12123022
Chicago/Turabian StyleMadetko-Alster, Natalia, Piotr Alster, Bartosz Migda, Michał Nieciecki, Dariusz Koziorowski, and Leszek Królicki. 2022. "The Use of Cerebellar Hypoperfusion Assessment in the Differential Diagnosis of Multiple System Atrophy with Parkinsonism and Progressive Supranuclear Palsy-Parkinsonism Predominant" Diagnostics 12, no. 12: 3022. https://doi.org/10.3390/diagnostics12123022